CD8+ T cell
Immune-Oncology Assays
- 2D/ 3D Tumour Killing Assay
- Antigen-specific CTL-CEFT (phenotype, proliferation, degranulation)
- MART-1 specific CTL- cytotoxicity
- T cell exhaustion
Autoimmunity Assays
- Activation
- Proliferation and function

Enzyme-Linked Immuno Spot (ELISpot) is a technique which quantifies immune cells of low abundance which release biomarkers such as cytokines in response to antigenic stimulation. ELISpot is a highly sensitive method to test immune modulators, novel vaccine candidates or de-risk immunogenicity testing in an antigen-specific CD4 and/or CD8 T cell assay.
Condition | Aim |
No Stimulation | Negative control |
PMA | Positive control |
CERI (CMV, EBV, RSV, Influenza) | MHC-I restricted peptide pool to evaluate modulation of CD8+ T-cell memory response |
CPI (CMV, Parainfluenza, Influenza) | Positive protein antigens to evaluate modulation of CD4+ T-cell memory response |
CEF (CMV, EBV, Influenza) | MHC-I restricted peptide pool to evaluate modulation of CD8+ T-cell memory response |
Cyclosporin A (CsA) | Inhibition of immune response |

Spot Forming Units (SPU) for IFN-γ per 100,000 PBMC from CERI, CPI and CEF antigens for three donors

Evaluation of therapeutic modulation of antigen-specific memory T cell responses to recall antigens
I. T cell response to Tetanus Toxoid, Influenza and PPD antigens

II. Dose response to Influenza antigen

Antigen specific T cells response to a recall antigens. (I) Healthy donors PBMC were stimulated with PHA-M or triple antigen cocktail (Tetanus Toxoid, Influenza and PPD). Cyclosporin was used as a reference treatment. (II) Dose response to Influenza antigen. CD4 and CD8 T cells proliferation was measured by flow cytometry using CTV dilutions.

Drug Discovery Tool
Find the right immune assay for your therapeutic area, modality and target using this interactive Drug Discovery Tool.